Invesco
VIR icon

Invesco’s Vir Biotechnology VIR Stock Holding History

Invesco’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.85M Buy
475,545
+54,213
+13% +$516K ﹤0.01% 2240
2026
Q1 		$3.78M Buy
421,332
+15,634
+4% +$125K ﹤0.01% 2299
2025
Q4 		$2.45M Sell
405,698
-12,258
-3% -$73K ﹤0.01% 2536
2025
Q3 		$2.39M Buy
417,956
+13,104
+3% +$67K ﹤0.01% 2556
2025
Q2 		$2.04M Sell
404,852
-728
-0.2% -$3.9K ﹤0.01% 2574
2025
Q1 		$2.63M Buy
405,580
+6,808
+2% +$60.5K ﹤0.01% 2436
2024
Q4 		$2.93M Buy
398,772
+2,574
+0.6% +$20.3K ﹤0.01% 2479
2024
Q3 		$2.97M Sell
396,198
-19,898
-5% -$173K ﹤0.01% 2462
2024
Q2 		$3.7M Sell
416,096
-32,864
-7% -$315K ﹤0.01% 2336
2024
Q1 		$4.55M Buy
448,960
+158,943
+55% +$1.62M ﹤0.01% 2295
2023
Q4 		$2.92M Sell
290,017
-165,534
-36% -$1.51M ﹤0.01% 2477
2023
Q3 		$4.27M Buy
455,551
+14,834
+3% +$212K ﹤0.01% 2288
2023
Q2 		$10.8M Sell
440,717
-54,591
-11% -$1.37M ﹤0.01% 1761
2023
Q1 		$11.5M Sell
495,308
-918
-0.2% -$23.5K ﹤0.01% 1683
2022
Q4 		$12.6M Sell
496,226
-9,720
-2% -$238K ﹤0.01% 1682
2022
Q3 		$9.76M Buy
505,946
+20,286
+4% +$516K ﹤0.01% 1804
2022
Q2 		$12.4M Buy
485,660
+445,472
+1,108% +$10.4M ﹤0.01% 1698
2022
Q1 		$1.03M Sell
40,188
-143,013
-78% -$4.24M ﹤0.01% 3053
2021
Q4 		$7.67M Buy
183,201
+148,193
+423% +$5.81M ﹤0.01% 2166
2021
Q3 		$1.52M Buy
35,008
+3,718
+12% +$161K ﹤0.01% 2938
2021
Q2 		$1.48M Buy
31,290
+13,892
+80% +$632K ﹤0.01% 2968
2021
Q1 		$892K Buy
17,398
+5,960
+52% +$321K ﹤0.01% 3094
2020
Q4 		$306K Buy
+11,438
New +$372K ﹤0.01% 3410
2020
Q3 		– Sell
-23,804
Closed -$975K – 3691
2020
Q2 		$975K Buy
+23,804
New +$799K ﹤0.01% 2812

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Invesco's VIR Position: Q2 2026 in Review

Invesco increased its Vir Biotechnology (VIR) stake by 13% in Q2 2026, buying an estimated $516K and bringing the position to 475,545 shares worth $4.85M. The position accounts for ﹤0.01% of the portfolio, ranked #2240.

Invesco first reported a position in VIR in Q2 2020 and has held it in 24 quarters since. The position peaked at $12.6M in Q4 2022. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Invesco held 475,545 shares of Vir Biotechnology worth $4.85M as of Q2 2026.
  • Invesco bought 54,213 Vir Biotechnology shares in Q2 2026, an estimated $516K.
  • Vir Biotechnology made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2240 holding.
  • Invesco first reported a position in Vir Biotechnology in Q2 2020 and has held it in 24 quarters since.
  • Invesco's Vir Biotechnology position peaked at $12.6M in Q4 2022.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.